此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)

2026年11月18日 更新者:Aurora Mirabile、IRCCS San Raffaele

Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study

The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.

研究概览

研究类型

介入性

注册 (估计的)

170

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participants are willing and able to give informed consent for participation in the study.
  2. Aged >=18 years
  3. Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
  4. Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
  5. Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.

Exclusion Criteria:

  1. Patients with a history of allergy to probiotics or severe allergic constitution
  2. Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
  3. Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
  4. Any previous RT to the head and neck region
  5. Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
  6. Allergies: history of known allergies to probiotics or to product excipients.
  7. Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
  8. Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
  9. Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
  10. Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
  11. Pregnancy and breastfeeding
  12. Contraindication related to probiotic composition
  13. Primary sites different from the ones described in inclusion criteria
  14. Patient unfit to cisplatin
  15. Immunocompromised Patients

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:placebo group

The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration

实验性的:group treated with probiotic: Streptococcus salivarius Evol12®

The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
EORTC QLQ-H&N35 score
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

次要结果测量

结果测量
措施说明
大体时间
days
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Time to onset (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Duration (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Numeric Rating Scale (NRS)
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%).

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
大体时间:It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年11月4日

首先提交符合 QC 标准的

2026年11月18日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月18日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅